Yisheng Biopharma Co Ltd, a biopharmaceutical company, has received a Pharmaceutical GMP Certificate from the China National Medical Products Administration (NMPA) for production of its Yisheng Junan product, the first lyophilised rabies vaccine without an aluminium adjuvant produced in China for medical use, it was reported yesterday.

The vaccine has demonstrated effective protection, contributing to the fight against rabies infection. The newly constructed state-of-art production facility is operated by the Liaoning Yisheng Biopharma subsidiary.

Zhang Yi, chairman of Yisheng Biopharma, said, 'As a vaccine manufacturer with a history dating back to 1994, Yisheng was the first private biopharmaceutical company to benefit from the dynamic evolution of vaccine technology in China and has long been a leader in technology innovation in rabies vaccine production. Now, we have invested approximately USD60m to build two new vaccine production facilities and successfully completed the GMP certification process.'